Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17142768 | 0.85 | IP6K1 (0.61) | RAB9ALMNANPC1TP53SMN1; SMN2 | |
| SCHEMBL2305565 | 0.84 | IP6K1 (0.59) | RAB9ALMNANPC1TP53SMN1; SMN2 | |
| SCHEMBL1890774 | 0.84 | SIRT6 (0.61) | RAB9ALMNANPC1TP53SMN1; SMN2 | |
| SCHEMBL27195824 | 0.84 | KDM4E (0.50) | TTRIP6K1HRH3KDM4EMAPT | |
| SCHEMBL1336438 | 0.83 | CHEK1 (0.51) | RAB9ALMNANPC1TP53SMN1; SMN2 | |
| SCHEMBL1335642 | 0.81 | IP6K1 (0.56) | RAB9ALMNANPC1TP53SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL14645192 | 0.81 | RAB9A (0.51) | RAB9ALMNANPC1TP53SMN1; SMN2 | |
| SCHEMBL30689227 | 0.81 | PRKDC (0.56) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL18394573 | 0.81 | PRKDC (0.56) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15923279 | 0.81 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2HTR6CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012487-B2 | Bicyclo-pyrazoles active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-04-21 | — | — | US | disclosed |
| US-9012487-B2 | Bicyclo-pyrazoles active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-04-21 | — | — | US | disclosed |
| US-9012487-B2 | Bicyclo-pyrazoles active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-04-21 | — | — | US | disclosed |
| EP-1999131-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-10-23 | — | — | EP | disclosed |
| EP-1999131-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-10-23 | — | — | EP | disclosed |
| US-8173659-B2 | Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-05-08 | — | — | US | disclosed |
| US-20110230470-A1 | SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-09-22 | — | — | US | disclosed |
| US-7947686-B2 | Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-24 | — | — | US | disclosed |
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2009-05-28 | — | — | US | disclosed |
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2009-05-28 | — | — | US | disclosed |
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2009-05-28 | — | — | US | disclosed |
| US-20090023745-A1 | Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-22 | — | — | US | disclosed |
| EP-1999131-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2008-12-10 | — | — | EP | disclosed |
| EP-1968976-A1 | SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007099171-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007099171-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007068619-A1 | SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230470-A1 | SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K3, MAP3K1, MAP3K19 | RAB9A 1056/4885LMNA 3253/4885NPC1 3499/4885 |
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | MAP3K19, CDK2, MAP3K1 | RAB9A 1065/4885LMNA 2859/4885NPC1 4057/4885 |
| US-20090023745-A1 | Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K19 | RAB9A 1056/4885LMNA 3253/4885NPC1 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.